SANA LOUISE JOHNSON-QUIJADA
- Type
- Physician · Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
- Where
- TEMECULA, CA
- NPI
- 1194882860
- Received
- $186,935 in 959 records, 2019 to 2025 ($185,650 general, $1,284 research)
- As principal investigator
- $2,359,506 of research payments to others in 353 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 69 | $14,703 |
| 2024 | General payment | 65 | $11,219 |
| 2023 | General payment | 170 | $67,218 |
| 2022 | General payment | 112 | $37,043 |
| 2021 | General payment | 197 | $21,359 |
| 2020 | General payment | 137 | $17,037 |
| 2019 | General payment | 203 | $17,068 |
| 2019 | Research payment | 6 | $1,284 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| IDORSIA PHARMACEUTICALS US INC | 121 | $65,866 | 2022–2024 |
| ABBVIE INC. | 151 | $49,562 | 2021–2025 |
| Otsuka America Pharmaceutical, Inc. | 191 | $42,623 | 2019–2025 |
| Allergan, Inc. | 124 | $23,262 | 2019–2021 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 8 | $1,323 | 2019–2022 |
| Lundbeck LLC | 129 | $1,017 | 2019–2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 82 | $608 | 2019–2022 |
| Vanda Pharmaceuticals Inc. | 24 | $408 | 2019–2025 |
| Sunovion Pharmaceuticals Inc. | 25 | $369 | 2019–2022 |
| Bausch Health US, LLC | 21 | $368 | 2022–2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 16 | $335 | 2022–2025 |
| Teva Pharmaceuticals USA, Inc. | 8 | $282 | 2023–2024 |
| Janssen Pharmaceuticals, Inc | 16 | $280 | 2019–2025 |
| Neurocrine BioSciences, Inc. | 12 | $243 | 2022–2025 |
| Eisai Inc. | 21 | $196 | 2020–2021 |
| Axsome Therapeutics, Inc. | 6 | $110 | 2022–2024 |
| Novo Nordisk Inc | 1 | $30 | 2025 |
| Alkermes, Inc. | 1 | $22 | 2019 |
| Merck Sharp & Dohme LLC | 1 | $12 | 2022 |
| Neuronetics, Inc. | 1 | $9 | 2025 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 100 | $153,620 |
| Travel and Lodging | 91 | $20,959 |
| Food and Beverage | 758 | $10,942 |
| Research payment | 6 | $1,284 |
| Education | 4 | $128 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | Lundbeck LLC | $25 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-12-16 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-12-15 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-12-02 | Otsuka America Pharmaceutical, Inc. | $12 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-11-24 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $9 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-11-22 | Novo Nordisk Inc | $30 | Food and Beverage | In-kind items and services | Wegovy Drug, Obesity | 2025 | |
| 2025-10-31 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-20 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-10-18 | Lundbeck LLC | $10 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-14 | Otsuka America Pharmaceutical, Inc. | $26 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-13 | Otsuka America Pharmaceutical, Inc. | $10 | Food and Beverage | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-10-13 | Otsuka America Pharmaceutical, Inc. | $0 | Food and Beverage | In-kind items and services | ABILIFY MAINTENA Drug, PSYCHIATRY | 2025 | |
| 2025-10-09 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-10-08 | Otsuka America Pharmaceutical, Inc. | $2,106 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-10-08 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-30 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $25 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-09-26 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-09-23 | Lundbeck LLC | $26 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-17 | Vanda Pharmaceuticals Inc. | $37 | Food and Beverage | In-kind items and services | FANAPT Drug, SCHIZOPHRENIA | 2025 | |
| 2025-09-11 | Bausch Health US, LLC | $24 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2025 | |
| 2025-09-09 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-09-08 | Neurocrine BioSciences, Inc. | $16 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-08 | Lundbeck LLC | $9 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-09-08 | Lundbeck LLC | $2 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-08-28 | Janssen Pharmaceuticals, Inc | $42 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-08-26 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-26 | ABBVIE INC. | $90 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-26 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-08-22 | Otsuka America Pharmaceutical, Inc. | $2,106 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-08-19 | Otsuka America Pharmaceutical, Inc. | $21 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-08-06 | Otsuka America Pharmaceutical, Inc. | $18 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-08-04 | Lundbeck LLC | $17 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-07-31 | ABBVIE INC. | $29 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-07-10 | Bausch Health US, LLC | $24 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2025 | |
| 2025-06-26 | ABBVIE INC. | $8 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-06-17 | Otsuka America Pharmaceutical, Inc. | $27 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-06-16 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-06-10 | Neurocrine BioSciences, Inc. | $14 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-05-20 | Otsuka America Pharmaceutical, Inc. | $17 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-05-20 | Otsuka America Pharmaceutical, Inc. | $2 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-05-13 | Lundbeck LLC | $30 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-05-05 | Bausch Health US, LLC | $21 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2025 | |
| 2025-04-28 | Lundbeck LLC | $12 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-04-23 | Janssen Pharmaceuticals, Inc | $20 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2025 | |
| 2025-04-23 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-04-18 | Otsuka America Pharmaceutical, Inc. | $351 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-04-17 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VIIBRYD Drug, NEUROSCIENCE | 2025 | |
| 2025-04-11 | Neurocrine BioSciences, Inc. | $17 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-04-07 | Vanda Pharmaceuticals Inc. | $16 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2025 | |
| 2025-03-19 | Vanda Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2025 | |
| 2025-02-26 | Vanda Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2025 | |
| 2025-02-22 | Lundbeck LLC | $19 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-02-21 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-02-21 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-02-19 | Bausch Health US, LLC | $15 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2025 | |
| 2025-02-19 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-02-19 | Otsuka America Pharmaceutical, Inc. | $6 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2025 | |
| 2025-02-11 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-02-11 | Neurocrine BioSciences, Inc. | $16 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-02-05 | ABBVIE INC. | $26 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-01-29 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-01-24 | Lundbeck LLC | $9 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-01-23 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-01-22 | ABBVIE INC. | $5 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-01-21 | Otsuka America Pharmaceutical, Inc. | $15 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2025 | |
| 2025-01-16 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $33 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2025 | |
| 2025-01-14 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2025-01-11 | Neuronetics, Inc. | $9 | Food and Beverage | Cash or cash equivalent | NEUROSTAR TMS THERAPY SYSTEM Device, NEUROSTAR TMS THERAPY SYSTEM | 2025 | |
| 2025-01-07 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2025 | |
| 2024-12-21 | Lundbeck LLC | $28 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-12-16 | Bausch Health US, LLC | $18 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-12-12 | ABBVIE INC. | $23 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-12-03 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2024 | |
| 2024-11-26 | Otsuka America Pharmaceutical, Inc. | $7 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2024 | |
| 2024-11-25 | Bausch Health US, LLC | $8 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-11-19 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-11-18 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-11-13 | Otsuka America Pharmaceutical, Inc. | $24 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-11-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2024 | |
| 2024-11-06 | Lundbeck LLC | $20 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-09-23 | Otsuka America Pharmaceutical, Inc. | $8 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-09-03 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2024 | |
| 2024-08-20 | IDORSIA PHARMACEUTICALS US INC | $21 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, Insomnia | 2024 | |
| 2024-08-07 | Otsuka America Pharmaceutical, Inc. | $789 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-08-07 | Janssen Pharmaceuticals, Inc | $25 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2024 | |
| 2024-08-07 | Bausch Health US, LLC | $24 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-08-06 | Otsuka America Pharmaceutical, Inc. | $10 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-07-30 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-07-30 | Vanda Pharmaceuticals Inc. | $20 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2024 | |
| 2024-07-15 | ABBVIE INC. | $25 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-07-15 | Vanda Pharmaceuticals Inc. | $17 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2024 | |
| 2024-07-10 | Bausch Health US, LLC | $13 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-07-09 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-07-09 | Neurocrine BioSciences, Inc. | $18 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-06-20 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-06-10 | Janssen Pharmaceuticals, Inc | $17 | Food and Beverage | In-kind items and services | INVEGA SUSTENNA Drug, Neuroscience | 2024 | |
| 2024-05-28 | Janssen Pharmaceuticals, Inc | $15 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2024 | |
| 2024-05-22 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-05-16 | Lundbeck LLC | $15 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-05-15 | Otsuka America Pharmaceutical, Inc. | $2,106 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-05-14 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-05-03 | Otsuka America Pharmaceutical, Inc. | $351 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-05-02 | Teva Pharmaceuticals USA, Inc. | $30 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-05-01 | Bausch Health US, LLC | $14 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-04-30 | Vanda Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2024 | |
| 2024-04-29 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-04-24 | Otsuka America Pharmaceutical, Inc. | $29 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-04-23 | Otsuka America Pharmaceutical, Inc. | $25 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-04-18 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-04-16 | Otsuka America Pharmaceutical, Inc. | $21 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-04-12 | Lundbeck LLC | $17 | Food and Beverage | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-04-10 | Bausch Health US, LLC | $17 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-04-09 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2024 | |
| 2024-03-28 | Neurocrine BioSciences, Inc. | $33 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-03-27 | Bausch Health US, LLC | $11 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-03-15 | Otsuka America Pharmaceutical, Inc. | $175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-03-14 | Otsuka America Pharmaceutical, Inc. | $11 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-02-29 | ABBVIE INC. | $12 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-02-28 | Bausch Health US, LLC | $20 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-02-22 | Teva Pharmaceuticals USA, Inc. | $25 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2024 | |
| 2024-02-21 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-02-13 | Otsuka America Pharmaceutical, Inc. | $21 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2024-02-08 | ABBVIE INC. | $3 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-02-07 | Bausch Health US, LLC | $16 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-01-31 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-01-31 | ABBVIE INC. | $7 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-01-31 | ABBVIE INC. | $6 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-01-30 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2024 | |
| 2024-01-25 | Axsome Therapeutics, Inc. | $16 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2024 | |
| 2024-01-23 | Bausch Health US, LLC | $1 | Education | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-01-18 | Neurocrine BioSciences, Inc. | $16 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2024 | |
| 2024-01-17 | Bausch Health US, LLC | $19 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2024 | |
| 2024-01-09 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2024 | |
| 2024-01-04 | Otsuka America Pharmaceutical, Inc. | $21 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2024 | |
| 2023-12-12 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-12-12 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-12-07 | Neurocrine BioSciences, Inc. | $19 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-12-07 | IDORSIA PHARMACEUTICALS US INC | $6 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-12-05 | Janssen Pharmaceuticals, Inc | $31 | Food and Beverage | In-kind items and services | SPRAVATO Drug, Neuroscience | 2023 | |
| 2023-12-05 | Otsuka America Pharmaceutical, Inc. | $17 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-11-30 | Vanda Pharmaceuticals Inc. | $24 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2023 | |
| 2023-11-21 | ABBVIE INC. | $49 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-21 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-21 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-21 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-20 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-20 | ABBVIE INC. | $20 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-11-20 | Bausch Health US, LLC | $15 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2023 | |
| 2023-11-16 | Teva Pharmaceuticals USA, Inc. | $30 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2023 | |
| 2023-11-13 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2023 | |
| 2023-11-09 | Otsuka America Pharmaceutical, Inc. | $29 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-11-02 | IDORSIA PHARMACEUTICALS US INC | $7 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-10-30 | Otsuka America Pharmaceutical, Inc. | $19 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-10-26 | Axsome Therapeutics, Inc. | $28 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2023 | |
| 2023-10-16 | Otsuka America Pharmaceutical, Inc. | $24 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-10-12 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14 | Food and Beverage | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2023 | |
| 2023-10-11 | Bausch Health US, LLC | $22 | Food and Beverage | In-kind items and services | APLENZIN Drug, Neurology | 2023 | |
| 2023-10-10 | Teva Pharmaceuticals USA, Inc. | $76 | Education | In-kind items and services | 2023 | ||
| 2023-10-10 | Teva Pharmaceuticals USA, Inc. | $27 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2023 | |
| 2023-10-05 | ABBVIE INC. | $24 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-10-05 | IDORSIA PHARMACEUTICALS US INC | $4 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-09-18 | Vanda Pharmaceuticals Inc. | $19 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2023 | |
| 2023-09-15 | IDORSIA PHARMACEUTICALS US INC | $2,632 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-09-15 | IDORSIA PHARMACEUTICALS US INC | $125 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-09-14 | Otsuka America Pharmaceutical, Inc. | $19 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-09-13 | Otsuka America Pharmaceutical, Inc. | $72 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-09-13 | Otsuka America Pharmaceutical, Inc. | $70 | Travel and Lodging | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-09-07 | Neurocrine BioSciences, Inc. | $34 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-09-07 | Otsuka America Pharmaceutical, Inc. | $21 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-09-06 | Otsuka America Pharmaceutical, Inc. | $2,106 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-09-06 | IDORSIA PHARMACEUTICALS US INC | $1,063 | Travel and Lodging | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-08-31 | IDORSIA PHARMACEUTICALS US INC | $124 | Travel and Lodging | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-08-31 | Otsuka America Pharmaceutical, Inc. | $29 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-08-31 | IDORSIA PHARMACEUTICALS US INC | $6 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-08-29 | ABBVIE INC. | $14 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-08-29 | Vanda Pharmaceuticals Inc. | $14 | Food and Beverage | In-kind items and services | HETLIOZ Drug, NON-24-HOUR SLEEP-WAKE DISORDER | 2023 | |
| 2023-08-25 | IDORSIA PHARMACEUTICALS US INC | $400 | Travel and Lodging | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-08-25 | IDORSIA PHARMACEUTICALS US INC | $286 | Travel and Lodging | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-08-25 | IDORSIA PHARMACEUTICALS US INC | $278 | Travel and Lodging | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-08-25 | IDORSIA PHARMACEUTICALS US INC | $19 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-08-24 | Axsome Therapeutics, Inc. | $15 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2023 | |
| 2023-08-17 | IDORSIA PHARMACEUTICALS US INC | $12 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-08-03 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-07-28 | IDORSIA PHARMACEUTICALS US INC | $2,632 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-07-25 | ABBVIE INC. | $2,250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-07-22 | IDORSIA PHARMACEUTICALS US INC | $125 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-07-17 | Otsuka America Pharmaceutical, Inc. | $22 | Food and Beverage | In-kind items and services | ABILIFY ASIMTUFII Drug, PSYCHIATRY | 2023 | |
| 2023-07-17 | Axsome Therapeutics, Inc. | $21 | Food and Beverage | In-kind items and services | Sunosi Drug, Neurology | 2023 | |
| 2023-07-13 | IDORSIA PHARMACEUTICALS US INC | $151 | Travel and Lodging | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-07-13 | Otsuka America Pharmaceutical, Inc. | $23 | Food and Beverage | In-kind items and services | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-07-12 | Otsuka America Pharmaceutical, Inc. | $1,140 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REXULTI Drug, PSYCHIATRY | 2023 | |
| 2023-07-10 | ABBVIE INC. | $28 | Food and Beverage | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-07-10 | ABBVIE INC. | $27 | Travel and Lodging | In-kind items and services | VRAYLAR Drug, NEUROSCIENCE | 2023 | |
| 2023-07-06 | Teva Pharmaceuticals USA, Inc. | $24 | Food and Beverage | In-kind items and services | Austedo XR Drug, Central Nervous System | 2023 | |
| 2023-06-30 | IDORSIA PHARMACEUTICALS US INC | $2,835 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-06-30 | IDORSIA PHARMACEUTICALS US INC | $124 | Travel and Lodging | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-06-30 | IDORSIA PHARMACEUTICALS US INC | $124 | Travel and Lodging | Cash or cash equivalent | QUVIVIQ Drug, INSOMNIA | 2023 | |
| 2023-06-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $48 | Education | In-kind items and services | CAPLYTA Drug, PSYCHIATRY | 2023 | |
| 2023-06-29 | Neurocrine BioSciences, Inc. | $13 | Food and Beverage | In-kind items and services | INGREZZA Drug, Neuropsychiatry | 2023 | |
| 2023-06-29 | IDORSIA PHARMACEUTICALS US INC | $8 | Food and Beverage | In-kind items and services | QUVIVIQ Drug, INSOMNIA | 2023 |
The latest 200 records of 959.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-01-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $5,476 | AN OPEN-LABEL, MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA | 2025 |
| 2024-07-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | VIKING CLINICAL RESEARCH | $4,573 | Proof of concept and DRF in BPD | 2024 |
| 2024-05-01 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $9,035 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2024 |
| 2024-03-21 | Otsuka Pharmaceutical Development & Commercialization, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $1,080 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALIN | 2024 |
| 2023-10-04 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $2,997 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2023 |
| 2023-08-30 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $2,128 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2023 |
| 2023-08-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $4,034 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2023 |
| 2023-08-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $5,335 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2023 |
| 2023-08-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | VIKING CLINICAL RESEARCH | $400 | Proof of concept and DRF in BPD | 2023 |
| 2023-07-06 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $2,128 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2023 |
| 2023-07-06 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $5,553 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2023 |
| 2023-06-03 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $2,537 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2023 |
| 2023-06-03 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $2,561 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2023 |
| 2023-05-03 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $3,333 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2023 |
| 2023-03-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $3,469 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2023 |
| 2023-03-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $4,613 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2023 |
| 2023-03-23 | Sage Therapeutics, LLC | VIKING CLINICAL RESEARCH | $13,806 | A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjec | 2023 |
| 2023-03-16 | Supernus Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $89 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-513 | 2023 |
| 2023-03-16 | Supernus Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $393 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-513 | 2023 |
| 2023-03-16 | Supernus Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $782 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-513 | 2023 |
| 2023-03-01 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $2,829 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2023 |
| 2023-03-01 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $4,386 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2023 |
| 2023-02-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $3,000 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2023 |
| 2023-02-01 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $863 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREAT | 2023 |
| 2023-02-01 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $3,704 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2023 |
| 2023-02-01 | Supernus Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $8,940 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-513 | 2023 |
| 2023-01-01 | Boehringer Ingelheim International GmbH | VIKING CLINICAL RESEARCH | $166 | Proof of concept and DRF in BPD | 2023 |
| 2022-12-29 | Supernus Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $9,726 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-513 | 2022 |
| 2022-12-29 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $4,755 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA | 2022 |
| 2022-12-22 | Otsuka Pharmaceutical Development & Commercialization, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $1,075 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERAB | 2022 |
| 2022-12-01 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $553 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA | 2022 |
| 2022-12-01 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $8,129 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2022 |
| 2022-11-03 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $5,982 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2022 |
| 2022-09-02 | Supernus Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $4,662 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-513 | 2022 |
| 2022-08-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $7,522 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALIN | 2022 |
| 2022-08-05 | Supernus Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $4,406 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-513 | 2022 |
| 2022-06-29 | Supernus Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $28,264 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-513 | 2022 |
| 2022-06-07 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $4,250 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2022 |
| 2022-05-26 | Otsuka Pharmaceutical Development & Commercialization, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $1,100 | A MULTICENTER, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF BREXPIPRAZOLE IN THE TREATMENT OF SUBJECTS WI | 2022 |
| 2022-05-19 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $1,514 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2022 |
| 2022-05-06 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $4,748 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA | 2022 |
| 2022-05-05 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $16,246 | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | 2022 |
| 2022-04-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $21,407 | Proof of concept and DRF in BPD | 2022 |
| 2022-04-07 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $398 | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | 2022 |
| 2022-03-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | VIKING CLINICAL RESEARCH | $924 | Proof of concept and DRF in BPD | 2022 |
| 2022-03-25 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $1,920 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2022 |
| 2022-03-17 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $1,364 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2022 |
| 2022-03-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $8,131 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA | 2022 |
| 2022-03-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $20,526 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2022 |
| 2022-02-22 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $5,000 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2022 |
| 2022-02-17 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $500 | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | 2022 |
| 2022-02-03 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $3,728 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2022 |
| 2022-02-03 | Otsuka Pharmaceutical Development & Commercialization, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $68,723 | A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND TRIAL OF FIXED-DOSE BREXPIPRAZOLE AS COMBINATION THERAPY WITH SERTRALIN | 2022 |
| 2022-02-02 | Supernus Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $7,950 | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF NV-513 | 2022 |
| 2022-02-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $4,500 | AN OPEN-LABEL MULTICENTER TRIAL TO ASSESS THE SAFETY AND TOLERABILITY OF LUMATEPERONE AS ADJUNCTIVE THERAPY IN THE TREA | 2022 |
| 2022-02-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $15,271 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS AD | 2022 |
| 2022-01-27 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $5,019 | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | 2022 |
| 2022-01-27 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $9,596 | A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY OF SAGE-217 IN THE TR | 2022 |
| 2022-01-20 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $9,475 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2022 |
| 2022-01-20 | Otsuka Pharmaceutical Development & Commercialization, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $13,559 | A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTI | 2022 |
| 2022-01-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $91,123 | Proof of concept and DRF in MDD | 2022 |
| 2022-01-01 | Boehringer Ingelheim International GmbH | VIKING CLINICAL RESEARCH | $499 | Proof of concept and DRF in BPD | 2022 |
| 2022-01-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $2,995 | Proof of concept and DRF in MDD | 2022 |
| 2022-01-01 | Boehringer Ingelheim International GmbH | VIKING CLINICAL RESEARCH | $499 | Proof of concept and DRF in BPD | 2022 |
| 2021-12-31 | Allergan, Inc. | VIKING CLINICAL RESEARCH LTD | $714 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-12-31 | Boehringer Ingelheim International GmbH | VIKING CLINICAL RESEARCH | $249 | Proof of concept and DRF in BPD | 2021 |
| 2021-12-28 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $4,617 | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJU | 2021 |
| 2021-12-16 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $2,751 | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-12-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $2 | Proof of concept and DRF in MDD | 2021 |
| 2021-12-14 | Allergan, Inc. | VIKING PHARMACEUTICAL TRIALS INC VIKING CLINICA | $17,241 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-12-09 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $1,489 | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-12-03 | Allergan, Inc. | VIKING PHARMACEUTICAL TRIALS INC VIKING CLINICA | $750 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-12-02 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $1,700 | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJU | 2021 |
| 2021-12-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $49 | Proof of concept and DRF in MDD | 2021 |
| 2021-11-18 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $1,000 | A STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-217 IN PARTICIPANTS WITH SEVERE POSTPARTUM DEPRESSION (PPD) | 2021 |
| 2021-11-10 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $1,786 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 |
| 2021-11-10 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $2,269 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 |
| 2021-11-10 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $16,257 | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-11-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $50 | Proof of concept and DRF in MDD | 2021 |
| 2021-10-21 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $10,066 | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-10-21 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $2,338 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 |
| 2021-10-21 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $1,270 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 |
| 2021-10-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $50 | Proof of concept and DRF in MDD | 2021 |
| 2021-09-23 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $5,283 | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-09-23 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $8,897 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 |
| 2021-09-14 | Allergan, Inc. | VIKING PHARMACEUTICAL TRIALS INC VIKING CLINICA | $5,263 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-09-09 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $500 | A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY OF SAGE-217 IN THE TR | 2021 |
| 2021-09-01 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | VIKING PHARMACEUTICAL TRIALS INC | $7,500 | A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF LUMATEPERONE AS ADJU | 2021 |
| 2021-09-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $51 | Proof of concept and DRF in MDD | 2021 |
| 2021-08-26 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $330 | Proof of concept and DRF in MDD | 2021 |
| 2021-08-13 | Allergan, Inc. | VIKING PHARMACEUTICAL TRIALS INC VIKING CLINICA | $9,095 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-08-12 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $9,381 | A COMPARATIVE STUDY OF SAGE-217 PLUS SERTRALINE VERSUS PLACEBO PLUS SERTRALINE IN ADULTS WITH MAJOR DEPRESSIVE DISORDER | 2021 |
| 2021-08-12 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $1,442 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 |
| 2021-08-09 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $80 | Proof of concept and DRF in MDD | 2021 |
| 2021-08-05 | Otsuka Pharmaceutical Development & Commercialization, Inc. | VIKING PHARMACEUTICAL TRIALS INC | $29,348 | A MULTI-CENTER, RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFECTIVENESS OF A DIGITAL THERAPEUTIC (CT-152) AS ADJUNCTI | 2021 |
| 2021-08-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $42 | Proof of concept and DRF in MDD | 2021 |
| 2021-08-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $26 | Proof of concept and DRF in MDD | 2021 |
| 2021-08-01 | Boehringer Ingelheim Pharma GmbH & Co.KG | VIKING CLINICAL RESEARCH | $52 | Proof of concept and DRF in MDD | 2021 |
| 2021-07-15 | Sage Therapeutics, LLC | VIKING PHARMACEUTICAL TRIALS INC | $169 | A PHASE 3, OPEN-LABEL, 1-YEAR STUDY OF THE SAFETY, TOLERABILITY, AND NEED FOR RE-TREATMENT WITH SAGE-217 IN ADULT SUBJEC | 2021 |
| 2021-07-13 | Allergan, Inc. | VIKING PHARMACEUTICAL TRIALS INC VIKING CLINICA | $22,008 | A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARIPRAZINE AS ADJUNCTIVE THERAPY IN MAJOR DEPRESSIVE DISORDER | 2021 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Temecula, CA, county Riverside County, CA, state California; placed by its city name.
| Measure | Place (city or town) Temecula, CA | County Riverside County, CA | State California |
|---|---|---|---|
| Population B01003 | 111,167 | 2,478,600 | 39,287,377 |
| Population, 2020 census P1 | 110,003 | 2,418,185 | 39,538,223 |
| Median age B01002 | 36.7 | 37.0 | 37.9 |
| Under 18 B01001 | 26.8% | 24.1% | 22.0% |
| 65 and over B01001 | 12.7% | 15.4% | 15.7% |
| Households B11001 | 36,536 | 775,335 | 13,548,091 |
| Foreign born B05002 | 15.9% | 21.9% | 27.0% |
| Median household income B19013 | $121,063 | $93,074 | $99,122 |
| Median family income B19113 | $130,015 | $103,984 | $113,346 |
| Per capita income B19301 | $47,086 | $38,317 | $49,513 |
| Poverty rate B17001 | 7.3% | 10.6% | 12.0% |
| Unemployment rate B23025 | 5.7% | 6.5% | 6.6% |
| Civilian labor force B23025 | 55,497 | 1,191,323 | 20,068,466 |
| Mean commute (minutes) B08013 | 36.3 | 33.8 | 28.7 |
| Bachelor's degree or higher B15003 | 38.8% | 25.6% | 37.1% |
| Housing units B25001 | 37,813 | 869,414 | 14,644,735 |
| Owner-occupied B25003 | 68.0% | 69.1% | 55.9% |
| Renters B25003 | 32.0% | 30.9% | 44.1% |
| Median home value B25077 | $679,700 | $557,300 | $734,700 |
| Median gross rent B25064 | $2,347 | $1,901 | $2,036 |
| White, not Hispanic B03002 | 48.4% | 31.0% | 33.8% |
| Black B03002 | 4.7% | 6.0% | 5.2% |
| Hispanic or Latino B03002 | 29.0% | 51.3% | 40.2% |
| Asian B03002 | 10.3% | 6.9% | 15.3% |
| American Indian and Alaska Native B03002 | 0.2% | 0.3% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Temecula, CA.
Comments